GLUT1 and Bcl-xL in relation to erythropoietin in human colorectal adenocarcinomas

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 741-745

  Wincewicz, Andrzej ^a   Baltaziak, Marek ^a,b   Kanczuga Koda, Luiza ^a,b   Koda, Mariusz ^a,b   Sulkowska, Urszula ^b   Sulkowski, Stanislaw ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Jedrzej Sniadecki Memorial Hospital   (Poland)

Author keywords

Anti apoptotic actions; Colorectal cancer; Erythropoietin; GLUT1

Indexed keywords

ERYTHROPOIETIN; GLUCOSE TRANSPORTER 1; PROTEIN BCL XL;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; COLORECTAL ADENOCARCINOMA; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; BCL-X PROTEIN; COLORECTAL NEOPLASMS; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; UP-REGULATION;

EID: 78149264310     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Tóvári J, Pirker R, Tímár J, Ostoros G, Kovács G, Döme B: Erythropoietin in cancer: an update. Curr Mol Med 2008; 8:481-91.
2. Pizzi S, Porzionato A, Pasquali C, Guidolin D, Sperti C, Fogar P, Macchi V, De Caro R, Pedrazzoli S, Parenti A: Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol. Histopathol 2009; 24:175-85.
3. Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, Campean V, Ong AC, Willam C, Gretz N, Eckardt KU: Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 2007; 170:830-42.
4. Park SK, Haase VH, Johnson RS: von Hippel Lindau tumor suppressor regulates hepatic glucose metabolism by controlling expression of glucose transporter 2 and glucose 6-phosphatase. Int J Oncol 2007; 30:341-8.
5. Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, Welch IM, West CM: Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Br J Cancer 2007; 96:1377-83.
6. Acs G, Xu X, Chu C, Acs P, Verma A: Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004; 100:2376-86. (Pubitemid 38657885)
7. Cooper R, Sarioǧlu S, Sökmen S, Füzün M, Küpelioǧlu A, Valentine H, Görken IB, Airley R, West C: Glucose transporter-1 (GLUT-1). A potential marker of prognosis in rectal carcinoma? Br J Cancer 2003; 89:870-6.
8. Wincewicz A, Sulkowska M, Koda M, Sulkowski S: Clinicopathological significance and linkage of the distribution of HIF-1alpha and GLUT-1 in human primary colorectal cancer. Pathol Oncol Res 2007; 13:15-20.
9. Wincewicz A, Sulkowska M, Koda M, Kanczuga-Koda L, Witkowska E, Sulkowski S: Significant coexpression of GLUT-1, Bcl-xL, and Bax in colorectal cancer. Ann. N. Y Acad Sci 2007; 1095:53-61.
10. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61:6548-54.
11. Wincewicz A, Sulkowska M, Koda M, Sulkowski S: Cumulative expression of HIF-1-alpha, Bax, Bcl-xL and P53 in human colorectal cancer. Pathology 2007; 39:334-8.
12. Diwan A, Koesters AG, Odley AM, Pushkaran S, Baines CP, Spike BT, Daria D, Jegga AG, Geiger H, Aronow BJ, Molkentin JD, Macleod KF, Kalfa TA, Dorn GW: Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis. Proc Natl Acad Sci USA 2007; 104:6794-9.
13. Koda M, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Kisielewski W, Baltaziak M, Wincewicz A, Sulkowski S: Expression of the Insulin Receptor Substrate 1 in primary tumors and lymph node metastases in breast cancer. correlations with Bcl-xL and Bax proteins. Neoplasma 2005; 52:361-3.
14. Wincewicz A, Sulkowska M, Koda M, Leśniewicz T, Kanczuga-Koda L, Sulkowski S: STAT3, HIF-1alpha, EPO and EPOR - signaling proteins in human primary ductal breast cancers. Folia Histochem Cytobiol 2007; 45:81-6.
15. Wincewicz A, Koda M, Sulkowska M, Kanczuga-Koda L, Sulkowski S: Comparison of STAT3 with HIF-1alpha, Ob and ObR expressions in human endometrioid adenocarcinomas. Tissue Cell 2008; 40:405-10.
16. Wincewicz A, Koda M, Sulkowska M, Kanczuga-Koda L, Wincewicz D, Sulkowski S: STAT3 and hypoxia induced proteins - HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal metastases of ductal breast cancers. Folia Histochem Cytobiol 2009; 47:425-30.
17. Chabowska AM, Sulkowska M, Chabowski A, Wincewicz A, Koda M, Sulkowski S: Erythropoietin and erythropoietin receptor in colorectal cancer. Int J Surg Pathol 2008; 16:269-76.
18. Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ: Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004; 214:243-51. (Pubitemid 39207986)
19. Conlon PJ, Walshe JJ, O'Donnell R, O'Donohoe A, Spencer R, Donohoe J, Carmody M: The use of recombinant human erythropoietin in end stage renal disease. Ir J Med Sci 1993; 162:17-9. (Pubitemid 23062326)
20. Sulkowska M, Wincewicz A, Chabowska A, Kanczuga-Koda L, Szymanska M, Koda M, Witkowska E, Sulkowski S: To give or not to give recombinant EPO to anemia endangered cancer patients. Prague Med Rep 2006; 107:281-9.
21. Pregi N, Vittori D, Pérez G, Leirós CP, Nesse A: Effect of erythropoietin on staurosporine-induced apoptosis and differentiation of SH-SY5Y neuroblastoma cells. Biochim. Biophys. Acta 2006; 1763:238-46.
22. Renzi MJ, Farrell FX, Bittner A, Galindo JE, Morton M, Trinh H, Jolliffe LK: Erythropoietin induces changes in gene expression in PC-12 cells. Brain Res Mol Brain Res 2002; 104:86-95.
23. Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, Henke M, Blau CA: Evaluating Erythropoietin-Associated Tumor Progression Using Archival Tissues from a Phase III Clinical Trial. Stem Cells 2009; 27:2353-61.